文献速递肿瘤 PET/CT甲状腺核医学

甲状腺转移作为结肠腺癌伴KRAS突变的首发表现:18F-FDG PET/CT的应用价值

Thyroid Metastasis as First Manifestation of a Colon Adenocarcinoma With KRAS Mutation: Usefulness of 18F-FDG PET/CT.
PubMed 文献 · Clin Nucl Med · 2017-01-01

本文报道一例74岁无症状女性,甲状腺细胞学提示恶性但来源不明,18F-FDG PET/CT揭示为Ⅳ期结肠腺癌伴KRAS突变及甲状腺、肺、肝多发转移。及时化疗后生存21个月。同期诊断甲状腺转移与原发性结肠腺癌极罕见,迄今仅报道5例,均行甲状腺手术,平均生存7个月。

要点

  • 18F-FDG PET/CT有助于明确甲状腺恶性病变的来源,本例检出Ⅳ期结肠腺癌多发转移。
  • 同期诊断甲状腺转移与结肠腺癌极罕见,迄今仅报道5例,均行甲状腺手术,平均生存7个月。
  • 本例及时化疗后生存21个月。

核心结论

  • 18F-FDG PET/CT在甲状腺细胞学提示恶性但来源不明时有助于明确原发肿瘤,本例检出Ⅳ期结肠腺癌伴KRAS突变及多发转移。

研究设计与样本

  • 本文为病例报告,报道一例74岁无症状女性,甲状腺细胞学提示恶性但肿瘤来源不确定。

主要发现

  • 18F-FDG PET/CT显示Ⅳ期结肠腺癌伴KRAS突变及甲状腺、肺、肝多发转移。
  • 及时制定化疗方案后患者生存21个月。
  • 同期诊断甲状腺转移与原发性结肠腺癌迄今仅报道5例,均行甲状腺手术,平均生存7个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The synchronous diagnosis of a thyroid metastasis and of the primary colon adenocarcinoma that produces it is very rare, with only 5 cases reported to date, all of them treated with thyroid surgery showing a mean survival of 7 months. An ¹⁸F-FDG PET/CT in an asymptomatic 74-year-old woman with a thyroid cytology suggestive of malignancy but uncertain about the origin of the tumor revealed an stage IV colon adenocarcinoma with KRAS mutation and multiple metastasis (thyroid, lung, and liver). A prompt therapeutic planning with chemotherapy allowed 21 months of survival.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lecumberri B, López E, Coronado M, et al. Thyroid Metastasis as First Manifestation of a Colon Adenocarcinoma With KRAS Mutation: Usefulness of 18F-FDG PET/CT. Clin Nucl Med. 2017. PMID: 28872477. doi:10.1097/RLU.0000000000001776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。